MARKETS / NASDAQ / INGN
NASDAQ · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · MID CAP

Inogen Inc. INGN

14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$348.7M
▲ 3.9% vs FY2024
EPS · FY25
$-0.86
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-12.4%
Net margin · FY25
-6.5%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 348.7M
Revenue, FY2025 · full 14-year series below
Revenue Net income
0.10.20.30.40.3-0.0201220152018202120242025
0.10.20.30.40.3-0.02016201920222025

The company lost 7 cents on every revenue dollar this year.

Per share
USD -0.86
Diluted EPS, FY2025
EPS
0.81.62.4-0.86201220152018202120242025
0.81.62.4-0.862016201920222025

The company pays no cash dividend.

Profitability
-12.4%
Return on equity, FY2025
ROE
8162432-12.4%201220152018202120242025
8162432-12.4%2016201920222025
Operating margin-8.7%
Net margin-6.5%
Return on assets-7.6%

Each USD of equity lost 12 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+2.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−2.6%
+2.5%
+8.2%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.03B
Shares outstanding, FY2025
0.000.03201220152018202120242025
0.020.032016201920222025
Change, 5 years+23.0%
Change, 10 years+37.7%

The share count grew 23% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 298.6M
total assets, end of FY2025
Total assetsUSD 298.6M
EquityUSD 192.2M
CashUSD 103.7M
Current ratio3.12×

Equity funds 64% of total assets.

History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.3
0.3
0.3
0.4
0.4
0.3
0.4
0.4
0.2
0.2
0.2
0.1
0.1
0.0
Operating income $B
−0.0
−0.0
−0.1
−0.1
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
−0.1
−0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
0.0
Net income $B
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
−0.86
−1.52
−4.42
−3.67
−0.28
−0.27
0.94
2.30
0.96
0.97
0.56
0.30
0.68
−19.97
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−12.4
−19.0
−40.8
−25.1
−1.8
−1.7
6.4
19.3
10.3
13.0
9.2
24.5
·
·
Shares out B
0.03
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.00
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
51 of 54
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 3 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed